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Abstract  
 
 Colorectal cancer is a global health concern. The high incidence of colorectal metastasis, 
mainly in the liver, triggers an increase of the mortality rate and greatly reduces the effective cure 
chances. For this reason, the investigation in the area is now focused on efficient detection and 
elimination of metastasis. Nanotechnology has become a fundamental research field since it provides 
promising perspectives regarding specific, oriented and sustained delivery of loaded nanoparticles for 
nanoteragnostic approaches. The current project aims to develop a nanocarrier, strategically 
constructed for specific administration, recognition and therapy of colorectal liver metastasis. 
Concerning this goal, two different approaches were concurrently developed:  a green-therapeutic 
technology and a novel nanoparticulate system, by nanoprecipitation and inverse microemulsion, 
respectively. The green approach focused on the encapsulation of a natural anticancer agent, phenetyl 
isothiocyanate (PEITC) in methoxy polyethylene glycol-co-poly ε-caprolactone (mPEG-co-PCL) 
nanoparticles. The development of this system did not advance significantly since more promising 
perspectives in a shorter period of time were obtained for the simultaneous developments of chitosan-
collagenase nanosystems. Chitosan-collagenase NPs were designed and developed for the first time 
due to their innovative properties regarding specificity in drug delivery and release. These 
nanosystems presented spherical shape and sizes in the range of 100 to 500 nm. The studies of pH and 
crosslinking influence in network swelling suggested higher swellings for more acidic pH and lower 
crosslinker contents. It was also postulated that the crosslinking degree influences differently the 
loading capacity and release efficiency of nanoparticles. As nanocarrier, chitosan-collagenase NPs 
demonstrated acceptable loads of the chemotherapeutic agent 5-fluorouracil for in vitro tests in HT29 
cell lines but low release efficiencies.  
 
Keywords: metastatic colorectal cancer; polymeric nanoparticles; drug delivery; mPEG-co-PCL; 
chitosan; collagenase 
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Resumo 
 
 O cancro coloretal é a terceira causa mundial de morte por cancro. A alta incidência de 
metástases, sobretudo no fígado, impulsiona a sua taxa de mortalidade e reduz substancialmente as 
hipóteses de cura. Por esse motivo, a investigação na área está focada na deteção e eliminação 
eficiente de metástases. A nanotecnologia tem demonstrado perspetivas promissoras no 
desenvolvimento de nanosistemas para libertação dirigida, controlada e continuada de agentes 
encapsulados para nanoteragnóstico. O presente trabalho tem como objetivo alargado o 
desenvolvimento estratégico de nanopartículas para administração, reconhecimento e terapia 
especializada do cancro coloretal metastático. Nesse intuito, foram desenvolvidos simultaneamente 
dois sistemas nanoparticulados. Uma abordagem ecológica focou a encapsulação de um agente 
anticancerígeno natural, PEITC, em mPEG-co-PCL, por nanoprecipitação. Até ao momento, o 
desenvolvimento deste nanosistema não avançou significativamente. Paralelamente, nanopartículas de 
quitosano-collagenase foram projetadas e desenvolvidas pela primeira vez por microemulsão inversa, 
devido às suas propriedades potenciais na otimização de terapêuticas. Estes nanosistemas revelaram 
morfologia esférica, com tamanhos na ordem dos 100 aos 500 nm. Os estudos da influência do pH e 
do grau de entrecruzamento no inchamento das redes nanoparticuladas sugeriram maiores 
inchamentos com o aumento de acidez e diminuição de entrecruzante. Postulou-se também que o 
aumento de entrecruzante confere à rede nanoparticulada maior capacidade de encapsulação e menor 
eficiência de libertação. A encapsulação de 5-fluorouracil demonstrou ser aceitável para testar em 
linhas celulares HT29, apesar da obtenção de baixas eficiências de libertação.  
 
Palavras-chave: cancro colorectal metastático; nanopartículas poliméricas; libertação de fármacos; 
mPEG-co-PCL; quitosano; colagenase   
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1. OBJECTIVES AND FRAMEWORK  
 
Figure 1.1 – Schematic representation of the thesis major goal and the designed approaches and its advantages 
for the purpose.  
  
The work developed during this master thesis is part of a project with higher scope, evaluated, 
approved and financed by iNOVA4health, as a promising translational program for advanced 
precision medicine. With a three year initial timetable, it has the final goal of obtaining specific 
nanoparticulate therapeutic systems for differential recognition of the several forms of metastatic 
colorectal cancer.  
 The master thesis focused on liver metastatic colorectal cancer, the most common 
metastasized site. The predicted tasks included the synthesis, characterization and functionalization of 
two parallel systems, with polymeric composition but different designs. One pathway was directed to a 
green approach, by using a clean and sustainable methodology for the encapsulation of two, 
independent agents, the coumarin – 6 (C6), a fluorescent marker used for imaging and phenetyl 
isothiocyanate (PEITC), a natural therapeutic drug. PEITC was chosen mainly due to its nutraceutical 
nature, contributing to a chemopreventive/chemotherapeutic green approach. In turn, since C6 is an 
agent with published results regarding its incorporation in mPEG-co-PCL system, its encapsulation 
was reproduced for comparative purposes with literature. Besides, its fluorescent properties can be 
potentially used for monitoring of nanoparticles during in vitro delivery assays.  
 As further explained below, methoxy poly (ethylene glycol) nanocarriers were chosen mainly 
because of their ‘green’, fast and simple synthesis procedure, well described by several authors in the 
literature and considered reliable, reproducible and adequate for pharmaceutical application. The 
Active target of 
metastatic 
colorectal cancer 
Green approach 
Novelty: 
encapsulation of 
the nutraceutic 
PEITC 
Ecological 
synthesis of the 
nano-vehicle 
Chemical 
approach 
Novel system 
Intrinsic target  
properties 
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reproduction of the published results would allow us to obtain monodisperse ecologic nanosystems 
whose composition would be immediately ready to perform functionalization studies without 
additional surface modifications. Besides, the quick synthesis would enable to initiate the 
functionalization assays in early stages, allowing the test and optimization of several biomarkers and 
its specificity for colorectal metastatic cancer.  
 Concurrently, a potentially innovative chemical approach to obtain a novel system was 
designed based on the nano-combined advantages of chitosan and collagenase compounds. It is 
expected to form a promising drug vehicle mainly due to its intrinsic biomarker properties, deeper 
penetration ability and pH response, which translates into selective accumulation in metastatic cancer 
cells, allows to reach the tumour inner core, and the drug delivery occurs preferentially in acidic 
tumoral pH. Moreover, since it was expected to functionalize nanoparticles surface to target metastatic 
colorectal cancer, the load capacity and release efficiency of this system was planned to be tested 
using a commonly chemotherapeutic agent applied in the treatment of this type of cancer, 5-
fluorouracil, for further in vitro assays in colorectal cancer cell lines.  
 Following this framework, the thesis structure will be divided into five main sections, 
Introduction, Experimental Section, Results and Discussion, Conclusions and Future work. The 
introductory section will first focus on the state of the art of colorectal cancer and nanotechnology, 
which are the bases of the project, then funnelling to the thematic contextualization of the principal 
materials involved in the project. The experimental section will contain a full description of the 
materials and procedures used. The section of results and discussion contains the outcomes of the 
experimental work developed as well and its evaluation, founded on the basis of literature available 
knowledge and expected results by comparative analysis. The Conclusions section will summarize the 
main outcomes of the experimental work and the future predicted tasks and further perspectives of the 
project will be summarized in the section of Future work. 
PROJECT MAIN GOALS: 
The main goal of this project was the synthesis and characterization of polymeric nanoparticles (PNPs) 
with nanometric size for parental administration of therapeutic drugs and further functionalization with 
specific markers for hepatic metastatic colorectal cancer.  
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2. INTRODUCTION 
 
2.1. Colorectal cancer epidemiology 
 Colorectal cancer is a global health concern, with an incidence rate rising over the years. In 
2012, presented an incidence of 1,36 million new cases, being the third cause of cancer death 
worldwide (Cancer Research UK, 2012). Regarding Europe, colorectal cancer represents the second 
position in terms of cancer occurrence and mortality, with register of about 447,000 cases and 215,000 
deaths. In Portugal, it is also the second most common and lethal cancer, with an estimated prevalence 
of about 7130 cases and 3800 deaths (Ferlay et al., 2013). The late diagnosis, which often occurs in 
advanced stages of the disease, mainly metastatic, severely contributes to the current mortality rates. 
The hepatic colorectal cancer metastasis is the most frequent (Masi et al., 2011). 
 
2.1.2. Conventional therapies 
… colorectal metastasis as a ‘stone’ on the path to healing. 
 The available therapies are used for cancer treatment in general, presenting low specificity and 
efficiency. The most common therapy applied to treat colorectal cancer is surgery which comprises 
surgical removal of the tumour and part of the contiguous healthy tissue. However, it is not efficient in 
advanced stages of the disease and not applicable in cases where the removal can compromise the 
organ function. There are other therapies aiming at the reduction or eradication of the tumour and/or 
metastasis but all of the available treatments have the disadvantage of affecting healthy cells.   
 Chemotherapy consists on the intravenous administration of anticancer agents, having a 
systemic effect, which causes several collateral effects. Besides, the cells can become resistant to the 
drugs, compromising the efficiency of the treatment.  
 Radiotherapy is mainly applied as adjuvant and despite being based on local administration of 
high energy radiation, has similar drawbacks regarding secondary effects and resistance.  
 On the other hand, ablation is based on local destruction by injection of a needle/probe into the 
tumour as source for direct treatment, but it is only efficient for small tumours or metastasis. 
Embolization can be applied for larger tumours/metastasis in the liver and consists on blocking the 
branches of the hepatic artery, since it is the main blood source of liver cancer cells. Despite the fact 
that normal cells remain supplied by the portal vein, the blood supply of liver tissue is reduced, which 
can affect its normal function. 
 The invasive effect of most of these treatments translates into a debilitated health for life. 
However, the cure of a primary tumour is achievable, normally by resection (Colorectal Cancer, 
American Cancer Society). The incurability of the disease is mainly related to the difficulty of 
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metastasis eradication. Normally, it is possible to control its progression for a certain period, but 
considering the present and reachable developments, prolonging patient’s life is for now, the only 
achievable goal. Scientific efforts are focused on countering the inability of curing this disease, aiming 
to achieve efficient, long-term survival and non-pejorative treatments (Masi et al., 2011; Raval et al., 
2014; van Hazel et al., 2016). 
 
2.2. Nanotechnology 
‘There's plenty of room at the bottom’ (Richard Feynman, 1959) 
  
 In the past decades, nanotechnology has arisen as a potential alternative to overcome the 
issues faced by the conventional medicine, regarding both diagnosis and therapy. The combination of 
nanoscale properties and cancer characteristics, allows by itself a preferential accumulation of 
nanosystems in the tumour environment (passive targeting), mainly due to the Enhanced Permeability 
and Retention (EPR) effect. The enhanced permeability in comparison with normal capillary systems 
occurs due to the leaky and defective vasculature of the tumours as a result of the extra and accelerated 
vascularisation in response to the nutritional needs required for the proliferative ability of cancer 
tissues. This phenomenon translates into gaps in the surrounding vessels, leading to extravasation of 
nanoparticles into cancer cells interstitium, whose retention is ensured by the characteristic absence of 
lymphatic drainage (Sinha et al., 2006). 
 In addition to the intrinsic EPR effect, there are other passive targeting strategies that can be 
applied to further specify the nanoparticles delivery, either by localized administration or by 
manipulating the nano formulation according to intrinsic characteristics of the delivery pathway. 
Regarding colorectal passive targeting, the main influences relate to gastrointestinal physiology, 
including pH, temperature, ionic strength, enzymes, mucoadherence and tumour microenvironment 
(Patel Parul, Satwara Rohan, & Pandya, 2012). Besides, there are active targeting approaches, based 
on delivery driven by functionalization with biomarkers, which restricts the distribution according to 
the specificity. The advanced state of investigation and exponential growth in molecular and genetic 
biology allows the identification of potential sensitive biomarkers and increasingly confined probes. 
This knowledge is very useful regarding the development of highly specific systems in terms of 
differential recognition, conferring strong specificity and efficiency to diagnosis and therapy 
approaches.  
 
 
 
5 
 
2.2.2.  Nanotechnology scale 
 
 The size range defined for nanoparticles is commonly 1 to 100 nm, according to the ISO 
(International Organization for Standardization) and ASTM International (American Society for 
Testing and Materials) standards. However, it is not possible to define unequivocal size limits since 
the physicochemical properties vary with the materials and surrounding conditions as well as its size 
dependence. Whereas the characteristics are acceptable under the predicted safety and risk parameters, 
and as long as the size is adequate and favourable for the application, the nano size range can be 
adjusted. Currently, according to the SCENIHR (Scientific Committee on Emerging and Newly 
Identified Health Risks), the standards remain ambiguous, being established differently, according to 
the area, material and application.  
 Regarding formulations for health purposes, it is important to ensure a sufficient residence 
time in the system to enable effective action. In this sense, the lower size limit for nanoparticles should 
be higher than 6 nm to prevent rapid renal clearance and above 15 nm to allow accumulation in liver 
and spleen, if required (Choi et al., 2007).  
 Another application with limited size required is internalization of nanoparticles in cells. 
Despite depending on many other factors as charge, shape and composition, the nanoparticles size 
greatly influences the occurrence and effectiveness of the cell uptake. For most cases, cellular 
internalization is described to occur up to 100 nm, with a maximum uptake varying from 50 to 100 nm 
(Shang, Nienhaus, & Nienhaus, 2014). However, there are some exceptions, as in the case of 
polymeric nanoparticles, for which there are published results that refer cell internalization of larger 
nanoparticles (until 500 nm) (Rejman et al., 2004; Shang, Nienhaus, & Nienhaus, 2014). 
 
2.3. Anticancer reduced scale approved therapies  
…if the wings of a butterfly can cause a hurricane, imagine what nanoscale can achieve. 
 
 In terms of current or ‘in test’ applications, the main approach is to use nanotechnology has 
bypass vehicle for the available or innovative therapies, using the nanosystems properties has an 
advantage. The most common application is the use of these systems for drug delivery, by active or 
passive targeting. The first approved nano-formulation by FDA (Food and Drug Administration) for 
this purpose, was Doxil, in 1995, a liposomal vehicle with a size range of 80 to 90 nm for the delivery 
of doxorubicin to treat metastatic ovarian cancer and AIDS (Acquired Immune Deficiency Syndrome)-
related Kaposi’s sarcoma. All the approved and marketed anticancer nanoformulations to date are 
summarized in Table 2.1, and the current clinical trials for the same purpose are shown in Table 2.2. 
Most of the developments were based on lipossomal formulations as the optisomal technology, a 100 
nm sphingomyelin/cholesterol liposome vehicle, with is first FDA approval in 2012 (Marqibo) for 
6 
 
vincristine delivery against Philadelphia chromosome-negative acute lymphoblastic leukemia. Two 
parallel systems using this technology, Alocrest and Brakiva, are currently in phase I clinical trials, for 
chemotherapeutic applications through vinorelbine and topotecan agents, respectively. Alocrest is 
being tested for breast and non-small cell lung cancer and Brakiva in non-small cell lung cancer, 
myelodysplastic Syndromes, ovarian cancer and acute myeloid leukemia. 
 The most recent anticancer FDA approved nanoformulation (2015) was Onivyde, also known 
as MM-398 or PEP02. It has been revised and marketed in 2015 from its first U.S approval in 1996. It 
is indicated for metastatic pancreatic cancer therapy, in combination with fluorouracil and leucovorin. 
Besides, is also involved in phase II clinical trials for colorectal cancer, gastric cancer and glioma and 
in phase I clinical trial for solid tumours. 
 In addition to the targeting ability, the systems composition can be modulated to be sensitive 
or responsive to a certain detection or therapy application, by external stimuli. In these cases, besides 
the vehicle ability, they can be involved in the diagnostic or therapeutic procedure. A therapy example 
is the SIRT (Selective Internal Radiation Therapy), which uses modulated systems with metallic 
specific characteristics to direct the treatment into an unique area, where those systems are 
preferentially accumulated. An approved SIRT approach is the administration via hepatic artery of 
microbeads coated with isotope yttrium-90 (Y-90) for pancreatic and hepatic liver cancer therapy, 
commercially available as TheraSpheres (20–30 μm spheres from BTG International Canada Inc) and 
SIR-spheres with 20-60 μm, prepared by Sirtex Medical Inc.  
 The most recent commercialized therapy with responsive characteristics is NanoTherm, with 
regulatory approval by European Union since 2010, recently (2016) marketed in Germany to treat 
brain tumours by thermal ablation. These 15 nm aminosilane-coated superparamagnetic iron oxide 
nanoparticles are in active expansion, with near perspectives of commercialization in European Union. 
Additionally, the treatment has been adapted to prostate cancer and submitted to FDA as an 
Investigational Device Exemption. The modulated Nanotherm devices for treating both prostate and 
brain cancer are now undergoing preclinical studies in the USA. 
 A nanosystem can have both active and passive contributions in a treatment, when combining 
the encapsulating ability with sensitive therapeutic properties to external stimuli, being a therapy 
vehicle and part of the treatment itself. A good example is ThermoDOX, a lysolipid thermally 
sensitive liposome encapsulating doxorubicin, which combined with thermal therapies, enhances its 
efficiency, both thermic and chemotherapeutic by localizing the heat (tumoral deeper penetration) and 
enhancing the drug liberation (improved release by lipossomal heating) 
 In terms of diagnosis approaches, the only nanoparticulate system with FDA approval  and 
clinical application (2001, Europe; 2002, Japan) was Resovist (Ferucarbotran), superparamagnetic iron 
oxide nanoparticles, with 120 to 180 nm, administrated as contrast/imaging agents for magnetic 
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resonance imaging (MRI). However, the product has been discontinued in Europe by the Bayer 
Pharma AG distributer, being marketed only by I’rom Pharmaceutical Co Ltd, Japan (Baetke, 
Lammers, & Kiessling, 2015; Haegele et al., 2014).  
 
2.3.2. Nanotherapies for colorectal cancer  
…personalized therapies are the future. 
  
 Concerning the major therapeutic target of this thesis, hepatic metastatic colorectal cancer, 
there is a FDA-approved nanotherapy regarding the adjuvant application of both Y-90 SIRT (Selective 
Internal Radiation Therapy using yttrium-90 - SIR-spheres) and chemotherapy (Raval et al., 2014) and 
published and ongoing phase trials of variants of the same goal (van Hazel et al., 2016). Additionally, 
there are nanoformulations in clinical phase trials. The ThermoDOX, a heat-activated liposome 
technology, is currently in phase II clinical trials for combined administration with HIFU (High-
Intensity Focused Ultrasound) in liver metastasis (and breast cancer) (Celsion Corporation). Other 
liposome-based formulation, containing a cisplatin analogue, is Aroplatin, in phase II development for 
intravenous chemotherapy of metastatic colorectal cancer. In turn, NK012 is a nanopolymeric micelle 
of PEG-polyglutamate copolymer incorporating SN-38, the active metabolite of irinotecan, currently 
in phase II studies for several cancers, including colorectal cancer (Ganji et al., 2015; Jin, Jin, & Hong, 
2014; Raval et al., 2014). 
 Considering the epidemiology of metastatic colorectal cancer, much effort is concentrated on 
finding alternative therapies to reduce mortality. In terms of nanotherapies regarding this application, 
there are many other formulations in preclinical trials or in current development but not yet ready for 
clinical evaluation. 
 
Table 2.1 - List of approved and marketed nanoparticulate systems for cancer therapy (updated to August 2016). 
Nanoparticulate 
system 
Commercial 
name 
Drug/Active 
ingredient 
Size 
range 
(nm) 
Application 
First year of 
approval 
Pegylated 
liposomal 
doxorubicin 
Doxil (Johnson 
& Johnson, 
USA) 
Caelyx 
(Janssen-Cilag, 
Europe) 
Evacet 
(Liposome 
company INC.,) 
Lipodox (Sun 
Pharma) 
Doxorubicin 
(Adriamycin) 
80-90 
Metastatic ovarian 
cancer 
 
HIV-related Kaposi 
sarcoma 
FDA, 1995 
Liposomal 
Daunorubicin 
Daunoxome Daunorubicin ≈ 45 
HIV-related Kaposi 
sarcoma 
FDA, 1996 
Cytarabine 
liposome 
DepoCyt Cytarabine 
3000-
30000 
Lymphomatous 
meningitis 
FDA, 
1999/2007* 
(continued) 
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Table 2.1 (continued) 
Nanoparticulate 
system 
Commercial 
name 
Drug/Active 
ingredient 
Size 
range/
nm 
Application 
First year of 
approval 
Non-pegylated 
liposomal 
doxorubicin citrate 
Myocet 
Doxorubicin 
hydrochloride 
≈180 
Metastatic breast 
cancer, plus 
cyclophosphamide. 
FDA, 2001 
(Europe & 
Canada) 
Microspheres 
Radionuclide/ 
yttrium-90 glass 
microspheres 
TheraSpheres Yttrium-90 
20000- 
30000 
Pancreatic and 
hepatic liver cancer  
FDA, 1999 
SIR-Spheres Yttrium-90 
20000- 
60000 
Liver metastatic 
colorectal cancer 
plus floxuridine  
FDA, 2002 
Tripartite viral 
particle 
Rexin-G 
Vector dnG1/C-
REX 
≈180 
Pancreatic cancer 
FDA orphan 
status, 2003 
Chemotherapy-
resistant solid 
malignancies 
Accelerated FDA 
Philippines 
approval,  
2007  
Soft tissue sarcoma 
and osteosarcoma 
FDA orphan 
status, 2008 
Albumin-bound 
Paclitaxel 
 
Abraxane Paclitaxel ≈ 130 
Metastatic breast 
cancer 
FDA, 2005 
Advanced NSCLC FDA, 2012 
Late-stage 
pancreatic cancer 
FDA, 2013 
PEG-asparaginase 
(Pegaspargase) 
Oncaspar L-asparaginase 50-200 ALL 
Initial US 
approval:1994 
FDA (revised), 
2006 
Micellar diblock 
copolymeric 
paclitaxel 
Genexol-PM 
(Samyang, 
Korean) 
Cynviloq 
(Sorrento 
Therapeutics, 
Inc. and 
IGDRASOL, 
Europe) 
Paclitaxel 20-50 
Metastatic breast 
cancer, NSCLC and 
ovarian cancer 
Approved and 
marketed in 
Korean (2007) 
Commercialized 
in Europe 
Liposomal 
mifamurtide 
muramyl tripeptide 
phosphatidyl 
ethanolamine 
Mepact Mifamurtide 
1000-
5000 
Osteosarcoma 
Orphan medicinal 
product, 2004 
Marketing 
authorization by 
EMA and 
European 
Commission 
(EU), 2009 
Aminosilane-
coated 
superparamagnetic 
iron oxide 
nanoparticles 
NanoTherm - 15 
Thermal ablation 
 in brain tumours 
Regulatory 
approval from 
EU, 2010 
Commerciallized 
in Germany, 
2016 
Liposomal 
vincristine 
sulphate/ 
Optisomal 
Vincristine 
Marqibo 
(Onco TCS) 
Vincristine ~100 
Philadelphia 
chromosome-
negative ALL 
FDA, 2012 
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Table 2.1 (continued) 
Nanoparticulate 
system 
Commercial 
name 
Drug/Active 
ingredient 
Size 
range 
(nm) 
Application 
First year of 
approval 
Paclitaxel micellar 
- Oasmia 
Pharmaceuticals 
(OAS-PAC-100/ 
Paclitaxel-XR-17) 
Paclical/ 
Apealea 
Paclitaxel 20-60 Ovarian cancer 
Marketed in  
Russia and CIS, 
2015 
Orphan status, 
(EMA-2006; 
FDA-2009) 
(Marketing 
registration in 
EMA and FDA, 
2016) 
Irinotecan 
nanoliposome 
Onivyde/ MM-
398/ PEP02 
Irinotecan ≈ 110 
Metastatic pancreatic 
cancer, in 
combination with 
fluorouracil and 
leucovorin 
Initial US 
approval:1996 
FDA (revised), 
2015 
EMA and FDA 
Orphan status, 
2011  
Note:*Year of accelerated approval and full approval, respectively. 
Abbreviations/Acronyms: FDA, Food and Drug Administration; EMA, European Medicines Agency; HIV, human 
immunodeficiency virus; PEG, polyethylene glycol; NSCLC, non-small cell lung cancer; ALL, acute lymphoblastic 
leukaemia; TNF, tumour necrosis factor; USA/US, United States of America; EU, European Union; CIS, Commonwealth of 
Independent States 
References: (Baetke et al., 2015; Haegele et al., 2014; Hafner et al., 2014; Hang, Cooper, & Ziora, 2016; Jin et al., 2014; 
Pillai, 2014; Raju et al., 2015; Raval et al., 2014; Sanna, Pala, & Sechi, 2014; van Hazel et al., 2016; Ventola, 2012; Weissig, 
Pettinger, & Murdock, 2014) and the corresponding and supplementing sources (FDA, EMA and pharmaceutical companies’ 
websites) 
 
Table 2.2 - List of nanoparticulate systems for cancer therapy in current clinical trials (updated to August 2016). 
Nanoparticulate system 
Drug/Active 
ingredient 
Potential application Phase Trial 
ThermoDOX 
Doxorubicin 
(Adriamycin) 
Primary Liver Cancer 
(mutual radiofrequency 
ablation) 
Clinical Phase III 
(FDA Orphan Drug 
Status, 2009; Fast 
Track designation) 
RCW breast cancer (plus 
local hyperthermia) 
Clinical Phase II 
Liver metastasis and 
breast cancer (plus 
HIFU) 
Clinical Phase II 
Paclitaxel Polyglumex/ 
Opaxio/ Xyotex/CT 2103 
Paclitaxel 
Ovarian cancer Clinical Phase III 
Advanced NSCLC 
Clinical Phase III 
(Fast Track 
designation, FDA) 
Malignant brain cancer 
(mutual Temozolomide 
and Radiotherapy) 
Clinical Phase II 
(FDA Orphan Drug 
Status, 2012) 
Advanced esophageal 
cancer 
Clinical Phase II 
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Table 2.2 (continued) 
Nanoparticulate system 
Drug/Active 
ingredient 
Potential application Phase Trial 
Lipoplatin (Lipossomal 
cisplatin, Nanoplatin for 
NSCLC) 
 
Cisplatin 
NSCLC 
adenocarcionomas 
Clinical Phase III 
 
Pancreatic cancer 
Clinical Phase II/III 
(EMA Orphan Drug 
Status, 2007) 
Breast cancer; Gastric 
cancer 
Clinical Phase II 
Malignant pleural 
effusion 
Clinical Phase I 
Micelplatin/Nanoplatin/NC-
6004 (Cisplatin polymeric 
micellar nanoparticles) 
Cisplatin 
Pancreatic cancer Clinical Phase III 
Bile duct cancer; 
Bladder cancer; NSCLC 
Clinical Phase II 
Head and neck cancer Clinical Phase I/II 
CPX351/ Vyxeos 
(Lipossomal 
cytarabine:daunorubicin) 
Cytarabine: 
Daunorubicin 
(5:1) 
AML 
Clinical Phase III 
(Orphan Drug Status – 
FDA, 2008; EMA-
2012) 
Breakthrough Therapy 
and Fast Track status, 
FDA) 
NK105 (Paclitaxel micelle) Paclitaxel 
Breast cancer, Japan Clinical Phase III 
Gastric cancer, Japan Clinical Phase II 
Solid tumours, Japan Clinical Phase I 
SP1049C (Micellar 
doxorubicin – pluronic 
F127:L61 (1:8) 
Doxorubicin 
Gastric cancer; 
Oesophageal cancer 
Clinical Phase II/III 
(FDA orphan drug 
status - 2007) 
EndoTAG-I/lipopack Paclitaxel 
Triple negative breast 
cancer and pancreactic 
cancer (mutual with 
gemcitabine) 
Clinical Phase II 
(FDA Orphan drug 
status, 2006) 
Atragen (Liposomal all trans- 
retinoic acid) 
Tretinoin APM Clinical Phase II 
Aurimmune/CYT-6091 
(colloidal gold-bound tumor 
necrosis factor) 
TNF NSCLC Clinical Phase II 
BIND-014 Docetaxel 
Squamous histology 
NSCLC and cervical, 
head and neck cancers 
Clinical Phase II 
MBP-426 (Lipossomal 
oxaliplatin) 
Oxaliplatin 
Metastatic gastric, 
gastro-esophageal 
junction or esophageal 
adenocarcinoma 
Clinical Phase II 
MM-302 (HER2- targeted 
pegylated liposomal 
doxorubicin) 
Doxorubicin Metastatic breast cancer Clinical Phase II 
Aroplatin (NDDP liposome) NDDP, cisplatin analog Metastatic CRC Clinical Phase II 
CRLX101 (Camptothecin- 
cyclodextrin-polyethylene 
glycol copolymer) 
Camptothecin 
Relapsed ovarian cancer 
(plus placitaxel or 
bevacizumab) 
Clinical Phase I/II 
(FDA Orphan drug 
status, 2015) 
Metastatic renal cell 
carcinoma (combined 
with bevacizumab) 
Clinical Phase II 
(FDA Fast Track 
designation) 
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Table 2.2 (continued) 
Nanoparticulate system 
Drug/Active 
ingredient 
Potential application Phase Trial 
LEP-ETU/NeoLipid 
(Paclitaxel liposome) 
Paclitaxel 
Metastatic breast cancer Clinical Phase II 
Ovarian cancer 
Clinical Phase I 
(FDA Orphan Drug 
Status, 2015) 
NK012/SN-38 nanopolymeric 
micelle 
Irinotecan SN-38 
(Irinotecan ative 
metabolite) 
Breast cancer; CRC; 
Multiple myeloma; 
Small cell lung cancer 
Clinical Phase II 
Solid tumours Clinical Phase I 
CRLX301 Docetaxel Advanced solid tumors Clinical Phase II 
SGT53 (Transferrin receptor-
Liposome-p53 Complex) 
p53-gene 
Glioblastoma; Pancreatic 
cancer 
Clinical Phase II 
Solid tumours Clinical Phase I 
Liposomal annamycin Annamycin ALL Clinical Phase I/II 
ProLindac(DACH-Pt polymer) DACH-Pt Ovarian Cancer Clinical Phase I/II 
Atu027 (Liposomal RNA 
interference) 
siRNA 
Pancreatic cancer Clinical Phase I/II 
Solid tumours Clinical Phase I 
Alocrest (Optisomal 
Vinorelbine tartrate) 
Vinorelbine 
Breast cancer and 
NSCLC 
Clinical Phase I 
Brakiva (Optissomal topotecan 
hydrochloride) 
Topotecan 
NSCLC, 
Myelodysplastic 
Syndromes, Ovarian 
Cancer and AML 
Clinical Phase I 
CALAA-01 (cyclodextrin 
polymer-based nanoparticles) 
siRNA 
Relapsed or refractory 
cancer 
Clinical Phase I 
Docetaxel- polymeric 
nanoparticle 
Taxane docetaxel Advanced Solid Tumors Clinical Phase I 
NK911 (Micellar 
doxorubicin)  
Doxorubicin Solid Tumors 
Clinical Phase I 
(Japan) 
NC-4016 (1,2- DACH-Pt- 
polymeric micelles) 
DACH-Pt Solid Tumors Clinical Phase I 
S-CKD602 (Pegylated 
liposomal CKD-602) 
Belotecan (CKD 602) Refractory solid tumors Clinical Phase I 
SGT 94 (Transferrin receptor - 
Lipossomal RB94 plasmid) 
RB94 plasmid DNA Solid Tumors Clinical Phase I 
Lipovaxin MM (Multi-
component liposomal 
nanoparticle-based) 
Melanoma antigens and 
IFNγ 
Malignant melanoma 
Clinical Phase I 
(Australia) 
C-VISA-BikDD liposome 
(DOTAP:cholesterol) 
Plasmid C-VISA 
BiKDD 
Pancreatic cancer Clinical Phase I 
C225-ILS-DOX (Doxorubicin 
anti-EGFR immunoliposomes) 
Doxorubicin Solid tumours Clinical Phase I 
Abbreviations/Acronyms: FDA, Food and Drug Administration; EMA, European Medicines Agency; RCW, Recurrent 
chest wall; HIFU, high intensity focused ultrasound; HER, Receptor tyrosine-protein kinase erbB-2; NDDP, Cis-
bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum II; DACH-Pt, diaminocyclohexane platinum; NSCLC, non-
small cell lung cancer; CRC, colorectal cancer; ALM, acute myeloid leukemia; ALL, acute lymphocytic leukemia; APM, 
Acute promyelocytic leukemia; IFNγ, interferon gamma 
References: Hafner et al., 2014; Hang et al., 2016; Jin et al., 2014; Pillai, 2014; Raju et al., 2015; Sanna et al., 2014; Ventola, 
2012  and the corresponding and supplementing sources (FDA, EMA and pharmaceutical companies’ websites) 
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2.4. The role of polymeric nanoparticles in nanotheragnostic development  
       …size and composition as favourable contribution. 
 
 Regarding biological applications, it is important to manipulate nanotechnology focusing on 
the primary needs of biosystems: biocompatibility, bioavailability and biodegradability. The 
combination of these properties allows acceptance by the biological system, delivery and effective 
action, active elimination of the systems and aims to prevent toxicity and immunogenic responses. 
Towards this purpose, polymers are a potential option, being widely applied as biomaterials in 
engineering, pharmacological and clinical developments (Marin et al., 2013). Polymeric chains consist 
on repeated simple and small units, whose arrangement and composition defines its physicochemical 
properties. This versatility allow to design and modulate systems to specific and diverse applications.  
The final properties required for a certain purpose, type of action and administration pathway, are 
possible to be optimized according to the type of formulation and by combination with other 
compounds.  
Despite the interest and potential of polymer-based nanoparticles, currently there are no approved 
therapies based on these systems for clinical application. However, there is a great focus on its 
development, as its shown by the ongoing clinical trials (Table 2.2). 
 
2.5. mPEG-co-PCL nanoparticles by nanoprecipiation 
…simple is better. 
 
 Methoxy polyethylene glycol-co-poly ε-caprolactone (mPEG-co-PCL) is an amphiphilic 
diblock copolymer resulting from ring-opening polymerization synthesis (Figure 2.1). In the field of 
nanotechnology, is described as a biocompatible and biodegradable drug delivery system with 
advantageous properties regarding sustained and controlled release.   
  
 
Figure 2.1 - Schematic representation of methoxy polyethylene glycol (mPEG) and ε-caprolactone (CL) 
copolymerization, to form copolymer mPEG-co-PCL, adapted from Xiong et al., 2015. 
 
 The mPEG-co-PCL nanoparticles present spherical shape, small sizes (from 100 to 140 nm) 
and uniform monodispersity, which contributes to a prolonged blood circulation time, enhances the 
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accumulation in tumours and endocytic uptake and prevents rapid elimination by the reticu-
loendothelial system (RES) (Baimark & Srisuwan, 2012; Baimark, 2009; Danafar & Schumacher, 
2016; Xiong et al., 2015). This nanosystems design is based on ‘synergetic’ combination of both poly 
ε-caprolactone (PCL) and methoxy polyethylene glycol (mPEG) in order to integrate the favourable 
properties of the two polymers in a unique system, bypassing their individual disadvantages. PCL is 
commonly designed as drug carrier due to its biocompatibility, non-cytotoxicity, high solubility, low 
glass transition temperature (Tg) and high drug permeability, conferred by its hydrophobicity. 
However this hydrophobic character and its semi-crystalline structure enhance its susceptibility to 
RES clearance and confer low degradation rates, respectively. The copolymerization with mPEG 
allows to achieve a positive equilibrium in terms of biodegradability, RES clearance reduction and 
higher blood circulation periods, because of its hydrophilicity and flexibility (Danafar & Schumacher, 
2016; Xiong et al., 2015). Besides, mPEG allows to functionalize nanoparticles surface without 
additional surface modifications and prevents nanoparticles agglomeration (Baimark & Srisuwan, 
2012), avoiding the use of surfactants which enable to maintain the ‘green’ character of the synthesis 
procedure – nanoprecipitation.  
 Nanoprecipitation, also called solvent displacement method, is a one step procedure with easy 
and rapid reproduction, based on the polymers relative solubility in two miscible solvents. The 
standard procedure normally takes advantage of polymer solvation in a non-toxic organic solvent, 
where the drug and surfactants (optional) are also soluble, forming a homogenous solution. When 
dropped into an aqueous solution, in which the polymer is less soluble (non-solvent), the fast diffusion 
of the solvent causes polymer precipitation. This phenomenon is responsible for nanoparticles 
formation with simultaneous drug entrapment (Minost et al., 2012). Since it is a mild process, 
requiring low energy (Xiong et al., 2015), it can be considered a green approach, when applied without 
surfactant.  
 
2.6. Chitosan 
…discovered 200 years ago (Braconnot). 
 
 Chitosan is a natural cationic polysaccharide that results from partial chitin deacetylation 
originating random linear combinations of β-1,4-linked glucosamine and N-acetyl-D-glucosamine 
units. Its intrinsic properties are greatly influenced by the molecular weight, varying from 10 to 1,000 
kDa, and deacetylation degree, normally in the range of 70-95% (Hamman, 2010). Given its high 
availability, low production cost and valuable properties regarding biocompatibility, biodegradability 
and low metabolic and immunogenic toxicity, it is repeatedly described in the literature as suitable 
delivery system in several different fields and applications. It is considered very promising regarding 
cancer because of its mucoadhesivity, tending to selective accumulate in mucous, preferentially in 
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anionic cancer cell surface due to its cationic nature. Other published characteristics are related with 
tumour growth suppression, immune system adjuvant and anti-inflammatory activity, which confer to 
this compound an anti-tumoral contribution (Pujana et al., 2013; Aruna et al., 2013; Park et al., 2010; 
Pujana et al., 2012). Besides, there are many benefits regarding other biomedical purposes – 
antifungal, antioxidant, anticholesterolemic, antimicrobial (Je & Kim, 2012) 
 Two major drawbacks in chitosan bio applications are its low solubility at physiologic pH 
(≈7.4) and its fast dissolution in the stomach (Park et al., 2010; Pujana et al., 2012), both explained by 
chitosan pKa (≈ 6.3-7) (Pujana et al., 2012). At pH above pKa, the non-protonated amino groups form 
strong hydrogen interactions within the chain, limiting external interactions and its solubility state. At 
acidic pH (below pKa), the weakening of inter-chain interactions due to amino protonation leads to 
chitosan dissolution. This behaviour can be controlled by using derivatives or combined systems. 
Moreover, this chitosan pH sensibility can be an advantage in terms of loading and strategic delivery,, 
for instance, to prevent drug release at physiologic pH, promoting its preferential release in tumour 
acidic environment or lisossomes or endossomes, in the case of internalization (Arteche Pujana et al., 
2014) . 
 
2.6.1. Chitosan-based nanosystems for colorectal cancer 
 
 The use of chitosan-based nanocarriers for pharmaceutical purposes leads to bioavailability 
enhancement and greater drug absorption and retention time (Aruna et al., 2013; Cerchiara et al., 
2015). Concerning cancer delivery, there are a lot of published applications to generic tumour cells 
(Lee et al., 2014; Mehrotra, Nagarwal, & Pandit, 2011; K. Park et al., 2007; Yoon et al., 2014) and 
specific cancers as lung (Maya et al., 2014), liver (Guan et al., 2012; Qi, Xu, & Chen, 2007; Zhu et al., 
2013), breast (Deng et al., 2014), brain (Veiseh et al., 2010), colon (Feng et al., 2015) and others. 
Several studies in this field have been done for colorectal cancer tissues aiming at diagnosis and 
therapeutics. In 2008, Yang, Chen, & Shieh reported in vivo promising results for a chitosan-folic acid 
conjugated system, carrying a contrast dye (indigo carmine) for endoscopic detection of colorectal 
cancer cells. Similar approaches referred chitosan nanoparticles and chitosan-folic acid nano-
conjugates as adequate carriers for oral administration of 5-aminolaevulinic acid (5-ALA), as 
fluorescent compound for colorectal cancer diagnosis. Those systems were developed with a 
perspective of further improvement, in order to reduce chitosan dissolution in the stomach (S. J. Yang 
et al., 2010; S.-J. Yang et al., 2009). Venkatesan et al presented, in 2011, promising outcomes from 
mouse human xenograph models for the use of a hydroxyapatite-chitosan nanosystem as transporter 
and delivery-agent for celecoxib and other drugs, aiming colon cancer treatment. In 2012, Xu et al 
published potential results for a chitosan-based nanosystem, modified with tripolyphosphate (TPP) to 
deliver interleukin-12 (IL-12). Focusing on the prevention of colorectal cancer liver metastasis, the 
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tests were made in vivo in mouse models, revealing an effective promotion of liver antitumor 
immunity. Another study, presented by Khatik et al (2013), refers the advantages of using Eudragit S 
100-coated chitosan nanoparticles (ES-CS-NPs) loaded with curcumin in comparison to chitosan 
nanoparticles, for colon cancer treatment. The ES-coating showed benefits regarding targeted release 
and the results suggest that ES-CS-NPs are more biocompatible. In turn, Malhotra et al (2013) studied 
pegylated chitosan nanoparticles tagged with CP15 peptide to target colon cancer cells, for therapeutic 
gene delivery of PLK1-siRNA. The in vivo experiments using this formulation in mouse xenograft 
model of colorectal cancer, showed promising results as non-invasive application for gene therapy. An 
in vivo investigation of the combined effect of 5-fluorouracil (5-Fu) and curcumin for the treatment of 
colon cancer, demonstrated that the individual encapsulation in thiolated chitosan nanocarriers 
improves drugs bioavailability and enhances their anticancer effect, when compared to non-
encapsulated combined drugs (Anitha et al., 2014). Feng et al (2015) produced a promising alternative 
for colorectal cancer therapy based on mucoadhesion improvement by using chitosan-carboxymethyl-
chitosan-CaCl2 (CS-CMCS-Ca
2+
) nanoparticles loaded with doxorubicin hydrochloride (DOX). A 
recent investigation (Ravikumar et al., 2016) resulted in the preliminary development and 
characterization of chitosan-hydroxy ethyl cellulose-poly vinyl alcohol, as suitable and useful 
nanofibers for 5-Fu-controlled release against colorectal cancer.  
 These developments are summarized in Table 2.3. 
   
Table 2.3 – List of chitosan-based nanoparticles, in development for colorectal cancer. 
Nanoparticulate 
system 
Functionalization Application Author/Year 
Chitosan-folic acid - 
Diagnostic: indigo carmine 
detection 
Yang et al., 2008 
Chitosan - 
Diagnostic: 5-aminolaevulinic acid 
delivery 
Yang et al., 2009 
Chitosan-folic acid - 
Diagnostic: 5-aminolaevulinic acid 
delivery 
Yang et al., 2010 
Chitosan - 
tripolyphosphate 
- Prevention: interleukin-2 delivery Xu et al., 2012 
Eudragit S 100-coated 
chitosan 
- 
Targeted therapy: curcumin 
delivery 
Khatik et al., 2013 
Chitosan-PEG-
CP15peptide 
PEG-CP15peptide Therapy:Biotin-siRNA delivery Malhotra et al., 2013 
Thiolated-chitosan - 
Therapy: combined delivery of 
curcumin and 5-fluorouracil 
(loaded independently) 
Anitha et al., 2014 
Chitosan-
carboxymethyl-
chitosan-CaCl2 
- 
Therapy: delivery of doxorubicin 
hydrochloride 
Feng et al., 2015 
Chitosan-Hydroxy 
Ethyl Cellulose-Poly 
Vinyl Alcohol 
- Therapy: 5-fluorouracil delivery 
Ravikumar et al., 
2016 
Abbreviation: PEG, polyethylene glycol 
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2.7. Collagenase application in nanotechnology 
  
 Collagenase is a proteolitic enzyme responsible for the digestion of native collagen. The 
degradation of collagen, an important component of the extracellular matrix, helps to bypass the 
penetration limitations imposed by that conjunctive barrier (Goodman, Olive, & Pun, 2007; Murty et 
al., 2014). Therefore, collagenase has been studied for anticancer nanomedicine or 
nanopharmaceutical applications, as active contributor in terms of achieving a deeper tumoral  
penetration and consequently, higher efficiency in nanoparticles accumulation and action. 
  Goodman, Olive, & Pun published in 2007 the first study corroborating collagenase 
advantages for this purpose. The results obtained revealed a four-fold enhancement of spheroids core 
penetration by collagenase-coated polystyrene nanoparticles in comparison to the control albumin-
coated nanoparticles. Another group showed that the pre-intravenous administration of collagenase in 
mice bearing mouse Lewis lung carcinoma, for further lipoplex delivery, increased tumour 
accumulation 1.5-fold and amplified the gene expression 2-fold (Kato et al., 2012). Moreover, in 2014, 
Murty et al., described nanoparticles functionalization with collagenase as a promising pathway to 
increase accumulation within tumours, based on tests of collagenase-pegylated gold nanoparticles in 
mice tumour xenografts, demonstrating an improvement of 35% in core accumulation, comparing to 
non-functionalized nanoparticles. 
 Recently, Villegas, Baeza, & Vallet-Regí (2015) presented an alternative and more complex 
model, for surface-transport of collagenase, aiming to avoid its exposure to blood circulating agents, 
as proteases. In this model, the authors attached pH-responsive polymeric-nanocapsules containing 
collagenase to the surface of mesoporous silica nanoparticles, to trigger collagenase release only in 
acidic conditions, similar to tumoral pH. Studies in three-dimensional models of human osteosarcoma 
cells showed considerable enhancement of tumours inner penetration. 
 The investigations did not report toxic effects of collagenase in human cells, being considered 
a safe additive for further developments. 
 The present work suggests a novel form of collagenase incorporation in the nanoparticulate 
systems and a new application for collagenase regarding colorectal cancer, as detailed below. 
 
2.8. Chitosan-collagenase nanoparticles by inverse microemulsion 
 
 Moilanen et al. published results in 2015 that corroborate the title of their publication, 
‘Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer’. The 
authors revealed an unexpected collagen expression in colon epithelia and its overexpression in 
colorectal cancer. The study suggests an overexpression enhancement in metastatic stages.  
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 Based on this, we postulated the use of collagen as a biomarker for metastatic colorectal 
cancer and we have designed a nano-delivery system incorporating collagenase as collagen recognizer, 
that would contribute for a preferential accumulation of nanoparticles in metastasis of colorectal 
cancer. 
 The collagenase incorporation was projected to occur through a genipin-based crosslink 
reaction, adapted from a chitosan-based nanospheres protocol (Pujana et al., 2013). This was possible 
due to the chemical groups involved in the reaction. As shown in Figure 2.2, the chitosan 
nanoparticles are synthesized by covalent crosslink between chitosan amine groups and the ester and 
dihydropyran ring of genipin. Since collagenase is also composed by amine groups, it can be 
crosslinked with genipin. Assuming collagenase integration as a chitosan-equivalent polymer in the 
synthesis procedure, simultaneous crosslink of both polymers is expected to occur, with no predefined 
order, forming chitosan-collagenase nanogels. 
 
 
Figure 2.2 - Schematic representation of crosslink between chitosan (left) and genipin (right), from Lins et al., 
2014. 
 
 The hybrid polymeric nanoparticles of chitosan and collagenase are expected to be 
biocompatible, bioavailable and biodegradable systems, combining the favourable properties of each 
polymer regarding specificity and efficiency of the delivery. Concerning nanoparticles accumulation, 
the use of collagen as biomarker allows to target colorectal cancer metastasis, with tumoral stronger 
adhesion and preferential accumulation conferred by chitosan mucoadhesivity and cationic nature. 
Besides, the enzymatic degradation of the extracellular tumour matrix allows the nanoparticulate 
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systems to reach the inner core, enhancing the therapeutic efficiency, also selectively directed to 
tumoral environment by using chitosan pH-sensitivity to trigger the drug release only in acidic 
environments, characteristic of tumoral surrounding. 
  The synthesis method reproduced, inverse microemulsion, also known as water–in-oil (W/O) 
microemulsion, is based on a thermodynamic equilibrium of water, oil and surfactant phases, in which 
the water amount is comparatively low, forming nanometric and monodisperse reverse micelles, with 
a polar inner core, containing polar or ionic compounds. The constant dynamic motion in solution - 
Brownian motion - leads to micelle collisions and fusion-fission occurrences, involving exchange and 
mixing of contents. The contact between reactants within micelles, forms ‘nanoreactors’, initiating the 
nanoparticles synthesis reaction by nucleation and controlled growth, limited and stabilized by the 
surfactant layer (Malik, Wani, & Hashim, 2012). 
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3. EXPERIMENTAL SECTION  
 
3.1.  Materials 
 
Methoxy poly(ethylene glycol) (mPEG, molecular weight Mn = 5,000 Da, Aldrich, Germany), ε-
caprolactone (CL) monomer (97%, Sigma-Aldrich, USA), Stannous octoate (Sn(Oct)2; 92,5-100%, 
Sigma, Japan), phenethyl isothiocyanate (PEITC, 99%, Aldrich, USA), coumarin-6 (C6, Santa Cruz 
Biotechnology, Dallas), chitosan (low molecular weight, Aldrich, USA), collagenase type I (Gibco 
Life Technologies, USA), genipin (98%, Wako chemicals, Germany). All solvents used were of 
analytical grade.  
 
3.2.  Synthesis and characterization of block copolymer mPEG-co-PCL 
 
The methoxy polyethylene glycol-co-poly ε-caprolactone  (mPEG-co-PCL) was synthesized by ring 
opening polymerization, adapted and optimized from Baimark, 2009; Baimark & Srisuwan, 2012; 
Xiong et al., 2015. The final synthesis was made as follows: 
 9.4 g of ε-CL (≈ 80 mmol), 2.2 g of mPEG (≈1  mmol) and 3.4 g of Sn(Oct)2 (≈ 0.1 mol% of 
monomer ε-CL) were added into a glass tube and submitted to a vacuum system under nitrogen 
refilling for about 2 hours. The tube was kept sealed and heated to ≈140°C in an oil bath for ≈24 h. 
The mixture was cooled to room temperature and dissolved in dichloromethane. The product was 
precipitated and washed in cold n-hexane or diethylether. After total evaporation of the precipitant, the 
final product was dried at ≈ 35°C, in an incubator. The copolymer structure was confirmed by 1H – 
NMR (nuclear magnetic resonance) in a Bruker Avance III 400MHz, Fallanden equipment, using 
CDCl3 as solvent. This protocol was optimized and requires further optimization to obtain a purer 
copolymer. 
 
3.3.  Synthesis of mPEG-co-PCL nanoparticles 
 
mPEG-co-PCL nanoparticles (NPs) were produced by nanoprecipitation, adapted and optimized from 
Baimark, 2009; Baimark & Srisuwan, 2012; Xiong et al., 2015.  
 10 mL of solvent were added to 10 mg of drug/marker and 100 mg of mPEG-co-PCL and 
submitted to vortex and sonification. The mixture was added dropwise to 100 mL of miliQ H2O, under 
stirring. The suspension was stirred overnight to remove the solvent and centrifuged to 15 000 rpm, 
4°C during 60 minutes. The pellet was lyophilized during 42h.  
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  Based on the cited procedures, the solvent used for both empty and C6-loaded NPs was 
acetone. For the loading of PEITC, a mixture of acetone:etanol (1:1) was used, taking into account the 
solubility properties of the copolymer and PEITC. 
 
3.4. Characterization of mPEG-co-PCL nanoparticles 
 
 The particles size was analysed by Dynamic Light Scattering (DLS) equipment (Zetasizer 
Nano Series, Malvern Instruments Ltd, UK). The samples for the analysis were dissolved in filtered 
bidistilled water and submitted to sonication and pre-equilibration at 25°C.  
 Field Emission Gun Scanning Electron Microscopy (FEG-SEM) (JEOL, model JSM7001, 
Japan) was also used to examine particle size and morphology. The samples were prepared for 
observation by covering with gold/palladium (Au/Pd), in a sputter coater (Quorum Technologies, 
model Q150TES). Micrographs of the prepared aliquots were taken at an acceleration voltage of 
15kV. 
 
3.5.  Synthesis of chitosan and chitosan-collagenase nanoparticles 
 
 The chitosan-genipin NPs were produced by inverse microemulsion, adapted from Pujana et al 
(2013). This synthesis was made to confirm the reproducibility of the procedure and as control, since it 
was applied for the development of the new system, chitosan-collagenase. 
 Two different microemulsions were prepared. To the first one, chitosan was prepared in 1% 
(v/v) aqueous acetic acid solution to a concentration of 10 mg/mL A mixture of cyclohexane:n-
hexanol:chitosan was prepared to a final ratio of 2.75:1:1. Triton X-100 was added dropwise until the 
solution became transparent. The second microemulsion was prepared by adding genipin in excess 
(100 mg per mL of miliQ H2O) to a mixture of cyclohexane:n-hexanol:miliQH2O (2.75:1:1). This 
microemulsion was added to the first one, under stirring. After 7 days of crosslinking reaction, at room 
temperature, the solution was added dropwise to excess ethanol. 
 
 The chitosan-genipin-collagenase NPs were produced by reverse microemulsion, adapted and 
optimized from the work of Pujana and collaborators (Arteche Pujana et al., 2013). 
  Two different microemulsions were prepared. To the first one, chitosan was prepared in 1% 
(v/v) aqueous acetic acid solution to a concentration of 10 mg/mL and mixed with collagenase 
dissolved in miliQ H2O, to a final ratio of 1:1. A mixture of cyclohexane:n-hexanol:chitosan-
collagenase were prepared to a final ratio of 2,75:1:1. Triton X-100 was added dropwise until the 
solution became transparent. The second microemulsion was prepared by adding genipin to a mixture 
of cyclohexane:n-hexanol:miliQH2O (2.75:1:1). The amounts of genipin were adapted to final ratios of 
10:1; 2:5; 1:5 and 1:10 (genipin:chitosan-collagenase). This microemulsion was added to the first one, 
21 
 
under stirring. After 7 days of crosslinking reaction, at room temperature, the solution was added 
dropwise to excess ethanol.  
 
3.5.1. Isolation and drying of chitosan and chitosan-collagenase nanoparticles  
 
 Several approaches were tested for obtaining dry and solvent/surfactant-free nanoparticles. 
 The first methodology tested was lyophilisation. The NPs were previously washed by several 
cycles of centrifugation at 8000 rpm for 15 minutes and ressuspension in ethanol. The final pellet was 
ressuspended in miliQ H2O, frozen in liquid nitrogen and dried by lyophilisation (72 hours, FreeZone 
Plus 4.5 Liter Cascade Freeze Dry System, Labconco).  
 The second approach resorted to rotary evaporator/rotavap equipment (Rotavapor R-210, 
Butchi, Switzerland) at 37°C, coupled to a vacuum controller (V-850, Butchi, Switzerland) and 
subsequent wash with diethyl ether to remove the surfactant and remaining impurities.  
 A third method aiming for a one-step procedure was tested using an adsorbent membrane 
(NADIR UP-10) coupled to a vacuum controller (V-850, Butchi, Switzerland). 
 The last procedure applied was NPs washing by several cycles of centrifugation at 8000 rpm 
for 15 minutes and ressuspension in ethanol. The final pellet was further washed by agitation in 
diethylether to remove remaining impurities and vestigial solvents or surfactant. 
 
3.5.2. Characterization of chitosan and chitosan-collagenase NPs 
 
 The nanoparticles size and morphology was studied recurring to FEG-SEM (JEOL, model 
JSM7001, Japan). The samples were prepared for observation by covering with gold/palladium 
(Au/Pd), in a sputter coater (Quorum Technologies, model Q150TES). Micrographs of the prepared 
aliquots were taken at an acceleration voltage of 15kV. 
 
3.5.3. 5-Fluorouracil loading into chitosan and chitosan-collagenase nanoparticles 
 
The following procedure was designed and optimized from Arteche Pujana et al., 2014. 
 Nanoparticles were suspended in a phosphate buffered saline (PBS) solution of 5´-fluorouracil 
(5´-Fu) at 20 or 40 ppm, according to a final NPs concentration of 1 or 3 mg/mL, respectively. These 
suspensions, prepared at pH 3 and 5.5 were stirred for at least 3h, for drug entrapment by swelling of 
the NPs network. Then, the pH was increased to values around physiologic pH (7.4) by adding NaOH 
and stirred during 1h, to diminish network swelling, avoiding drug liberation. The samples were 
centrifuged at 6000 rpm for 20 minutes and the supernatants collected and analysed by 
spectrophotometry at 264 nm to determine the encapsulation efficiency. To remove superficial drug, 
the nanoparticles were washed with PBS pH 7.4. 
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3.5.4. 5-Fluorouracil in vitro release 
 
The release occurred by submitting the load nanoparticles to acidic PBS solutions (pH 3 and 
5.5), under agitation during at least 3h. The samples were centrifuged at 6000 rpm for 20 minutes. The 
amount of 5-Fu in the supernatants was determined at 264 nm, by Beer-Lambert law. Calibration 
curves were previously prepared for 5-Fu quantification. The samples were prepared by successive 
dilution of a 100 ppm stock solution for final concentration of 80, 50, 20, 10, 5, 3, 2 and 1 ppm. The 
stock solutions and dilutions were performed using PBS at pH 3, 5.5 and 7.4. 
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4. RESULTS AND DISCUSSION 
4.1. Block copolymer mPEG-co-PCL 
 
The final yield of the copolymer synthesis was calculated by the formula: 
% yield =
Final weight
Initial weight
 100 
 The final weight corresponds to the mass of the powder obtained after synthesis and 
precipitation. The initial weight corresponds to the sum of the measured masses of the reagents 
involved in the synthetic procedure (ε-CL and mPEG). 
 During the optimization phases, the final yield was increased from 12 to 88%. It is expected to 
be enhanced in further stages of optimization. 
 
Figure 4.1 – 1H-NMR spectrum obtained for chemical characterization of mPEG-co-PCL, obtained by a 
preliminary synthesis, similar to procedure described (data supported by literature published spectra - Figure 8.1, 
in appendix.) 
 
 During the polymer precipitation, it was noticed that the solution became yellow, which is a 
possible indicator of ε-caprolactone presence (specification sheet – Sigma Aldrich), probably resulting 
from an incomplete reaction. This supposition was confirmed by the NMR spectrum obtained from the 
precipitated powder (Figure 4.1). The δ = 1,249 ppm is not associated to any chemical group of mPEG-
co-PCL. Analysing the individual components and intermediary forms involved in the 
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copolymerization, it was noticed that it may correspond to the isopropyl end group of poly(ε-
caprolactone), since it has a similar chemical shift (Long et al., 2010, Figure 8.2-b). Despite being a 
confirmation of the initiation of ring opening polymerization (Figure 8.2-a), the presence of PCL also 
evidences the existence of intermediary compounds resultant from incomplete copolymerization 
between mPEG and PCL. 
 The other unexpected signal (δ ≈ 0,9ppm), is a triplet characteristic of methyl groups, which 
can result from the solvents used to precipitate the polymer, n-hexane or diethylether.  
 In addition, it is possible to observe interferences in the signals that confirm the existence of 
impurities in the product obtained by copolymerization. Therefore, the procedure was optimized until 
a higher degree of purity was achieved. The protocol described in the experimental section allowed to 
obtain the purest copolymer - Figure 4.2. By comparative analysis with published NMR spectra 
(Figure 8.1 in Appendix), it was assumed that the synthesized copolymer had an acceptable purity for 
preliminary studies regarding nanoparticles formulations. However, it was not possible to fully 
eliminate the precipitant interference, as it is possible to see at δ ≈ 0,9 ppm. For further studies, 
namely cellular tests, it is crucial to ensure the obtention of highly pure copolymer, solvent-free, to 
guarantee the reliability for in vitro and in vivo applications. 
 
Figure 4.2 - 
1
H-NMR spectrum obtained for chemical characterization of mPEG-co-CPL, synthesized by the 
described procedure (data supported by literature published spectra – Figure 8.1, in appendix.) 
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4.2. mPEG-co-PCL nanoparticles 
  
Firstly, the protocol described above was performed, for obtaining empty nanoparticles, as control of 
the reproducibility.  
 The DLS analysis of the empty mPEG-co-PCL nanoparticles synthesized from a set of 
optimization stages, showed progression in terms of polydispersion decrease - Table 4.1.  
 
Table 4.1 - DLS results obtained for empty mPEG-co-PCL nanoparticles, in different stages of optimization, 
ordered by progression (ascending from 1 to 3). 
 
 
 
 
 
 
 
 As indicated in the table, the maximum sizes measured by the DLS decreased during 
optimization, presenting median PdI values of 1, 0.402 and 0.386, for crescent optimization degrees, 
respectively. This PdI decrease resulted from less agglomerates in suspension and measurement of 
narrow size ranges, as clearly observed in Figure 4.3.  
 
 
Figure 4.3 - Representation of size ranges obtained for the principal stages of optimization, ordered by 
progression (ascending from 1 to 3). 
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 The measurements of initial optimization stages indicated the presence of significant amounts 
of agglomerates (sizes over 1000 nm), which can be due to interference of impurities or particles 
agglomeration, measured by the DLS equipment as a single ‘body’ - Figure 4.4.  
 
Figure 4.4 - Schematic representation of nanoparticles agglomeration, adapted from the online page of Product 
and Process Engineering - Delft University of Technology. 
 The agglomeration of particles can occur naturally due to chemical favourable stabilization or 
because of remaining compounds or solvents of the synthesis, that during the dry procedure, form a 
‘resin’ that holds the nanoparticles as an unique structure. The occurrence of both phenomena was 
confirmed by observation of SEM images of the samples. 
 
Figure 4.5 – FEG-SEM images obtained from samples obtained during optimization stages of mPEG-co-PCL 
nanoprecipitation. Left – Impurities (non spherical structures); Right – resin effect. (Scale bar: left top - 10 µm; 
left bottom - 1 µm; right top - 1 µm; right bottom - 100nm).  . 
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 In the left images contained on Figure 4.5, it is possible to observe non spherical structures 
that corroborate the existence of impurities, probably resulting from the copolymer powder. In the 
right images, it is visible the agglomeration of nanoparticles in a resin-like structure.  
 After a few stages of optimization, were obtained similar results to those reported in the 
literature, that describe an obtainment of spherical monodisperse nanoparticles, with published 
comparable sizes: less than 100 nm (Baimark, 2009), less than 140 nm (Baimark & Srisuwan, 2012), 
in the range of 120 to 140 nm (Xiong et al., 2015) and around 128 nm (Danafar & Schumacher, 2016). 
The data collected by these authors regarding size ranges and respective polydispersity, are 
summarized in Table 4.2. 
 
Table 4.2 – Summarized information regarding size range and polydispersity of mPEG-co-PCL nanoparticles, 
according to the results published by the cited authors. 
mPEG-co-PCL NPs 
size (nm) 
PdI References 
]80 ; 100[ - (Baimark, 2009) 
]120 ; 140[ - (Baimark & Srisuwan, 2012) 
]120 ; 140[ 0.121 - 0.136 (Xiong et al., 2015) 
]120 ; 150[ 0.166 (Danafar & Schumacher, 2016) 
Notes: The ‘-‘ means that there is no available data regarding that parameter.  
Abbreviations: mPEG-co-PCL NPs, methoxy polyethylene glycol-co-poly ε-caprolactone nanoparticles; PdI, polydispersity index. 
 
 The DLS results for the last mPEG-co-PCL NPs synthesis (Table 4.1 - progression stage 3) 
indicated measured sizes ranging from 99 to 241 nm, with a median size of 158 nm, near to the 
published ones - Table 4.2 - and a median polydispersity index of 0.385, significantly reliable for 
considering the sample as monodisperse. The higher size values probably correspond to agglomerates 
in suspension that interfere and compromise the reliability of DLS results.  
 To confirm the nanoparticles size and morphology, the sample obtained in the latest stage of 
optimization was analysed by FEG-SEM - Figure 4.6. As expected, the nanoparticles presented 
spherical shape and monodisperse sizes, around 100 nm. 
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Figure 4.6 – FEG-SEM images of mPEG-co-PCL nanoparticles, synthesized in the latest stage of optimization 
(Scale bar: left - 1 µm; right - 100nm).   
 
 4.2.1. Loaded nanoparticles 
 
 In parallel to the synthesis of empty NPs, the production of coumarin-6 (C6)-loaded 
nanoparticles was reproduced and optimized from (Xiong et al., 2015), and used for the design of 
PEITC encapsulation. The loaded-NPs were first analysed by DLS, and compared to the empty 
nanoparticles, as schematically represented in Figure 4.7 and Figure 4.8.  
 
 
Figure 4.7 - Graphical representation of the intensity of each size range (population), obtained for empty and 
loaded mPEG-co-PCL NPs, indicating its median intensity (columns) and the respective variations (error bars). 
The population 1corresponds to the smallest size range and population 3 identify the larger ones.  
 
 The existence of more than one population size for the same nanoparticles sample is defined 
by the relative intensity measured for different sizes in suspension. If different sizes are identified in a 
significant percentage (>20%), they are considered individual population sizes, revealing a broad 
dispersity of nanoparticles. 
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Figure 4.8 – Graphical representation of the population sizes obtained for empty and loaded mPEG-co-PCL 
NPs, indicating their median size (columns) and the respective variations (error bars). 
 
 As observed in the graphs of Figure 4.7 and Figure 4.8, three population sizes were identified 
for mPEG-co-PCL NPs loaded with PEITC and 2 population sizes for mPEG-co-PCL NPs loaded with 
C6, in comparison to the one population presented by the empty nanoparticles. This information and 
the remaining data collected from DLS measurements are summarized in Table 4.3 
 
Table 4.3 - DLS results obtained for the loaded mPEG-co-PCL nanoparticles, in the first stages of synthesis in 
comparison the optimized results obtained for empty nanoparticles. 
 
Population 
Size range 
(nm) 
Median size 
(nm) 
Intensity 
range (%) 
PdI range 
Agglomerates 
intensity 
range (%) 
mPEG-PCL 1 ]99;241[ 159 80 - 100 0.220 - 0.774 0 - 20 
 
mPEG-PCL 
+ PEITC 
 
1 ]93;130[ 102 18 - 53 
0.332 - 1.000 0 - 10 2 ]142;324[ 203 53 - 82 
3 ]626;906[ 660 30 - 79 
mPEG-PCL 
+ C6 
1 ]44;126[ 59 18 - 38 
0.467 - 1.000 0 - 23 
2 ]156;743[ 263 42 - 100 
Note: The agglomerates intensity range was considered for sizes above 1000 nm. 
 
 The DLS measurements for C6-loaded nanoparticles indicate a major incidence of sizes 
between 156 and 743 nm, presenting high polydispersity and a significant incidence of agglomerates. 
Since coumarin-6 is fluorescent, it interferes with the analysis, therefore, DLS methodology is not 
adequate to analyse this sample. The C6-loaded mPEG-co-PCL NPs was thus analysed by FEG-SEM, 
in order to obtain reliable results regarding size and morphology - Figure 4.9. 
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Figure 4.9 – FEG-SEM images obtained for coumarin-6-loaded mPEG-co-PCL nanoparticles (Scale bar: 1 µm). 
 
 As seen in the figure, there are spherical structures with sizes higher than 100 nm. However, 
the presence of non-defined structures is clear, problably corresponding to non-encapsulated coumarin 
or other impurities. This results suggests that the nanoprecipitation was not efficient. Since the 
encapsulation of C6 is already published by other authors but there is no significant description data 
available, the experimental studies were focused on the development of PEITC-loaded NPs, as a 
novelty concerning the mPEG-co-PCL nanoparticulate system. 
 The DLS measurements regarding PEITC-loaded nanoparticles (Table 4.3) indicate a main 
prevalence of sizes in the range of 142 to 324 nm, presenting also a high incidence of measured sizes 
above 626 nm, probably due to agglomeration.  
 In subsequent studies to test the stability of nanoparticles in suspension, the sample of mPEG-
co-PCL loaded with PEITC was submitted to agitation to promote solvation, enhancing the 
monodispersity of the suspension. Additionally, the nanoparticles concentration in solution was also 
studied since it influences the agglomeration. By diluting the sample, it is expected to decrease the 
agglomeration phenomenon. Furthermore, the occurrence of sedimentation was studied by submitting 
the nanoparticles to several periods of rest. The sedimentation tends to increase the number of 
agglomerated structures. 
 These conditions were reproduced experimentally, in a standard sample with an initial 
concentration around 1 mg/mL. The effect of those conditions in size dispersion is exemplified in 
Figure 4.10, from data collected by DLS analysis. The remaining information is summarized in Table 
4.4. 
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Figure 4.10 – Summary of the median sizes measured by DLS and its variations, before and after submitting a 
sample of mPEG-co-PCL loaded with PEITC to periods of agitation, dilution and subsequent rest. 
 
 After agitation, it was noticed the prevalence of intermediate and bigger sizes in comparison to 
the standard solution, confirming the existence of agglomerates in solution that ‘mask’ the smaller 
sizes. After dilution, the results remain similar to those obtained after agitation, in terms of sizes and 
intensities - Figure 4.10 and Table 4.4 – which can be due to insufficient time to reach a new 
equilibrium in solution. Another possibility is the interference of impurities or free drug in solution, 
further confirmed by the FEG-SEM images - Figure 4.11 and Figure 4.12. 
 
Table 4.4 . DLS results obtained for the PEITC loaded mPEG-co-PCL nanoparticles, before and after submitting 
the sample to periods of agitation, dilution and subsequent rest. 
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Population Size (nm) 
Median 
size (nm) 
PdI range 
Intensity 
range (%) 
mPEG-PCL + 
PEITC 
1 ]45;119[ 92 0.446 - 1.000 8 - 20 
2 ]168;319[ 283 0.574 - 0.953 42 - 100 
3 ]409;933[ 686 0.446 - 1.000 59 - 92 
After 
agitation 
1 ]155;301[ 192 0.583 - 0.977 15 - 36 
2 ]462;891[ 518 0.185 - 0.632 85 - 100 
After dilution 
1 ]124;269[ 199 0.743 - 0.909 7 - 50 
2 ]458;833[ 613 0.002 - 1.000 50 - 100 
After 1h rest 
1 ]66;99[ 87 0.303 - 0.606 5-6 
2 ]467;681[ 575 0.294 - 0.606 94-100 
 
After 24h rest 
 
1 ]91;170[ 108 0.295 - 0.526 8 - 36 
2 ]264;459[ 359 0.295 - 0.542 43 - 100 
3 ]626;716[ 639 0.410 - 0.526 57 - 71 
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 Concerning the sedimentation studies, a decrease of about 50% of the smallest sizes was 
observed after 1 hour and a pronounced intensity increase of bigger sizes after 24h. These results 
confirm the strong influence of sedimentation in agglomerates formation. The subsequent analysis by 
FEG-SEM suggests that the agglomerates probably do not correspond to nanoparticles. From the 
images obtained, the most similar with spherical structures that may correspond to nanoparticles is 
represented in Figure 4.11, with diameters around 100 nm. However, given the surrounding 
agglomeration, it is not possible to make reliable conclusions regarding the nature of those structures. 
 
 
Figure 4.11 – FEG-SEM image of structures that may correspond to nanoparticles obtained by nanoprecipitation 
of mPEG-co-PCL and PEITC (Scale bar: 100nm).   
 
 The remaining images obtained by FEG-SEM show larger structures, with no defined shape. 
Some examples are represented in Figure 4.12.  
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Figure 4.12 - FEG-SEM image of non-defined structures, obtained by nanoprecipitation of mPEG-co-PCL and 
PEITC (Scale bar: left top - 10 µm; left bottom - 10 µm; right top - 1 µm; right bottom – 10 µm).  
 
 As observed, there is no uniformity between the structures. Images from different aliquots of 
the same sample show an undefined arrangement. In most cases it appears as films or networks, which 
may correspond to impurities or contaminants. Alternatively, it can result from unexpected 
interactions involving the reactants used in the procedure (drug, copolymer and solvents) which may 
have interfered with the nanoprecipitation procedure. It is not possible to conclude whether there was 
an efficient encapsulation by nanoprecipitation since the larger structures can be ‘masking’ the 
existence of nanoparticles. To clarify these hypotheses, further developments and optimizations need 
to be designed and performed. However, given the available time and since the concurrent 
development of nanoparticles of chitosan-collagenase showed promising results, the supplementary 
developments concerning the encapsulation of PEITC in mPEG-co-PCL was scheduled for future 
tasks. 
 
4.3. Chitosan and chitosan-collagenase crosslinked nanoparticles 
 
The synthesis of chitosan nanoparticles was reproduced as control, to compare the results obtained in 
the first developments concerning size and morphology and to verify the influence of collagenase 
incorporation in the loading and release assays patterns of chitosan nanoparticulate systems. After 
reproduction of chitosan NPs and comparative evaluation needed to consider the chitosan-collagenase 
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nanosystems as reproducible and promising, the experimental developments were directed to the 
individual optimization of the chitosan-collagenase nanoparticles. 
 The synthesis of chitosan and chitosan-collagenase nanoparticles was submitted to several 
stages of optimization, mainly in terms of scale-up, to obtain significant amounts. 
The final yield of the each synthesis was calculated by the formula: 
% yield =
Nanoparticles dry weight
 eactants weight
 100 
The reactants used in the synthesis were chitosan and genipin in the case of chitosan nanoparticles and 
chitosan, collagenase and genipin in the case of chitosan-collagenase nanoparticles. 
 In the first syntheses, collectable amounts of nanoparticles were not obtained, so it was not 
possible to calculate the final yield for those stages. The first measurable amounts obtained by initial 
scale-up, had yields around 10% for chitosan NPs and 9% for chitosan-collagenase NPs. Further 
optimization regarding the system of interest – chitosan-collagenase NPs – gave yields from 58 to 
65%. 
 Since chitosan-collagenase nanoparticles are a novel system, never synthesized before, the 
first step after synthesis was to confirm to reproducibility of the procedure for this new system, by 
comparison to the standard – chitosan NPs. The analysis by DLS it is not adequate for these samples, 
because the nanoparticles are intrinsically coloured. The characterization regarding size and 
morphology was obtained by FEG-SEM. The first output, for samples dried by lyophilisation is 
represented in Figure 4.13. 
 
Figure 4.13 – FEG-SEM images of nanoparticles dried by lyophilisation. Left – chitosan nanoparticles; right – 
chitosan-collagenase nanoparticles (Scale bar: 100nm).   
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 As observed in the images, it was possible to accurately reproduce spherical chitosan 
nanoparticles with monodisperse sizes, in a range mostly below 50 nm (Figure 4.13, left), as described 
by the authors followed for this synthesis (Arteche Pujana et al., 2013).  Concerning the chitosan-
collagenase NPs (Figure 4.13, right), the structures are not clearly defined, thereby, it is difficult to 
obtain an unambiguous characterisation.  
 During synthesis optimization stages, regarding increased yield and time saving, other 
methodologies were tested for nanoparticles isolation and drying. Rotavapor equipment was used for 
vacuum-accelerated solvent evaporation and further surfactant elimination by washing with 
diethylether. This approach was designed to reduce the manipulation steps needed to wash and dry the 
nanoparticles, since it avoids the initial washing cycles needed for lyophilisation and significantly 
reduces the drying time (72 hours by lyophilisation and less than 24 hours using rotavap). The images 
obtained for the samples dried using this technique, are represented in Figure 4.14. 
 
 
Figure 4.14 - FEG-SEM images of nanoparticles dried using rotary evaporation. Left – chitosan nanoparticles; 
right – chitosan-collagenase nanoparticles (Scale bar: top - 100 nm; bottom - 10 µm). 
 
 The chitosan NPs (Figure 4.14, left) remained similar to those previously obtained, in terms of 
size and morphology, but presented a highly agglomerated organization. In turn, the chitosan-
collagenase nanoparticles obtained in this synthesis (Figure 4.14, right) presented a well defined 
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spherical structure, with higher and more dispersed sizes, in the range of 100 to 500 nm. Observing the 
image with higher magnification (right, top, 100 nm scale), it is clear the rough surface of chitosan-
collagenase NPs, which may indicate fusion phenomena. Besides, these NPs also present a high 
agglomeration degree, which suggests the presence of surfactant, highly viscous, acting as a resin. The 
drying by solvent evaporation concentrates all the surfactant, which highly difficults its removal, this 
being the major drawback of rotavap drying. Additionally, although nanoparticles may be stable at the 
temperature applied in this technique (37°C), calorimetric studies should be done to confirm their 
thermal stability. 
  An alternative approach, aiming for nanoparticles isolation and drying in a one-step procedure, 
was nanoparticles vacuum filtration using an adsorbent membrane - NADIR UP-10. This membrane 
presented stable parameters in terms of colour, size, thickness, weight and malleability for adsorption 
of the solvents used in inverse microemulsion. The membrane is impermeable to the nanoparticles, 
isolating them from the microemulsion by adsorption of the liquid phase, which is pulled out by the 
vacuum system. Micrographs of chitosan and chitosan-collagenase nanoparticulate samples dried by 
this method are shown in Figure 4.15. 
 
Figure 4.15 - FEG-SEM images of nanoparticles dried using NADIR UP-10 membrane. Left – chitosan 
nanoparticles; right – chitosan-collagenase nanoparticles (Scale bar: top – 100 nm; bottom - 10 µm).   
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 Chitosan nanoparticles showed similar characteristics (Figure 4.15, left), compared to previous 
syntheses. Concerning chitosan-collagenase, there were technical problems during the synthesis that 
compromised the efficient formation and isolation of nanoparticles. The images (Figure 4.15, right) 
show agglomerated structures tending to spherical shape, suggesting an incomplete synthesis.  
 Despite the prospects of NADIR-UP 10 membrane, its application in the dry procedure was 
not continued due to the unexpected drawbacks detected. Even with the combined action of membrane 
adsorption and vacuum, a high percentage of surfactant was detected, involving the nanoparticles in a 
matrix-like structure, as is possible to observe in the lower magnification image of chitosan (Figure 
4.15, left, bottom, 10 µm scale). Moreover, the membrane is very expensive, with restricted utilization 
and has low processing capacity for the purpose (slow process for small sample amounts). 
 The last tested procedure regarding the obtention of solvent/surfactant-free nanoparticles was 
simply based on washing cycles with ethanol and diethylther. The synthesized nanoparticles dried by 
this process are represented in Figure 4.16. 
 
 
Figure 4.16 - FEG-SEM images of nanoparticles washed and dried using ethanol and diethylether. Left – 
chitosan nanoparticles; right – chitosan-collagenase nanoparticles (Scale bar: top - 100 nm; bottom - 1 µm).  
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 The chitosan NPs features remained identical, although highly agglomerated, probably due to 
inefficient surfactant elimination. However, for chitosan-collagenase nanoparticles, this procedure was 
the most favourable, showing a lower agglomeration degree. In terms of size and morphology, this 
batch of chitosan-collagenase nanoparticles presents spherical shape and size ranges around 100 to 
500 nm. 
 Summarizing the characterization by FEG-SEM, the nanoparticles synthesized presented 
spherical forms, with monodisperse sizes for chitosan NPs, under 50 nm, and broad size ranges for 
chitosan-collagenase NPs, ranging from 100 to 500 nm.  
 The obtention of visible alterations in nanoparticles characteristics by collagenase addition, 
suggest an efficient incorporation of collagenase in the nanoparticulate system. Comparing to chitosan 
NPs standards, the chitosan-collagenase nanoparticles presented larger sizes, different colour and less 
adhesion (easier dispersion). 
 
4.3.1. Load and release of 5-fluorouracil  
 
 The encapsulation of 5-fluorouracil (5-Fu) in these nanoparticles was chosen since it is a 
chemotherapeutic agent, widely used in the treatment of colorectal cancer, which is the target of the 
work in development. 
The encapsulation efficiency (EE) was calculated by the formula: 
EE     =
 5 Fu total  5 Fu supernatant
 5 Fu total
 100 
The [5-Fu]total refers to the concentration of 5-Fu added to the nanoparticles and the [5-Fu]supermatant 
indicates the concentration of 5-Fu in the supernatant after nanoparticles centrifugation. The EE 
obtained in the first load assays and the remaining important parameters are summarized in Table 4.5. 
Table 4.5 – Estimated parameters after 5-fluorouracil encapsulation in chitosan and chitosan-collagenase 
nanoparticles, at a pH of 5.5. 
 EE (%) 
[5-Fu] 
(µM) 
µg 5-Fu/mg NPs 
Chitosan ]38;42[ ]58;64[ [7.6 ; 8.3] 
Chitosan-
collagenase 
[34;37[ ]51;56[ [6.7 ; 7.2] 
  Note: These data refers to a standard nanoparticles concentration of 1 mg/mL. 
 The 5-Fu loading data obtained for both nanosystems is similar, with slightly higher values for 
chitosan NPs. Since the loads are made by swelling of the nanoparticles network due to chitosan pH 
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sensitivity, it is normal to obtain higher encapsulation efficiency in chitosan nanoparticles in 
comparison to chitosan-collagenase, that have lower chitosan amounts.   
 The subsequent release assays suggests null drug liberation at pH 5.5, which may indicate an 
insufficient swelling of the network. However, in the cellular context, there are other conditions that 
can promote the release (enzymes, temperature, etc.). The values of average inhibiting concentration 
(IC50) given by the IPOLFG (Instituto Português de Oncologia de Lisboa Francisco Gentil) partners 
for the HT29 cell line (human colorectal adenocarcinoma cell line) were 2.39 µM for proliferation and 
11.79 µM for viability. Since the 5-Fu loaded concentration is higher than IC50 values, loaded 
nanoparticles were prepared and tested in vitro in that cell line, by the Colon Pathology Study Group 
(IPOLFG). The preliminary assays were not conclusive due to high agglomeration of nanoparticles 
and interference of its intrinsic colour in the standard procedures. Presently, optimization is being done 
to bypass those problems.  
 In parallel, studies regarding the network swelling were developed, only for the novel system, 
chitosan-collagenase nanoparticles, since its reproducibility was confirmed by comparative analysis 
with the chitosan NPs, used as control.  
 In the previous syntheses, excess amounts of genipin (genipin:polymer ratio of 10:1) were 
used to guarantee a maximum crosslinking. To evaluate the network swelling constraint by influence 
of the crosslinking degree, new syntheses were reproduced using 10%, 20% and 40% of genipin 
amounts, corresponding to 1:10; 1:5 and 2:5 ratios of genipin:polymer, respectively. To 
simultaneously evaluate the influence of acidity in the network swelling, the nanoparticles load and 
release were tested at the standard pH 5.5 and at pH 3. These studies were done in fixed time periods. 
The data regarding encapsulation efficiency, drug loaded concentration and relative amount of 5-Fu 
and nanoparticles, are summarized in Table 4.6. 
Table 4.6 - Estimated parameters obtained by 5-fluorouracil encapsulation at pH 5.5 and 3, in chitosan-
collagenase nanoparticles, synthesized using genipin:polymer ratios of 1:10, 1:5 and 2:5. 
Genipin:polymer 
ratio 
pH EE (%) 
[5-Fu]loaded 
 (µM) 
µg 5-Fu/mg NPs 
1:10  
3 73 214.37 8.42 
5.5 60 137.57 6.03 
1:5  
3 62 182.00 7.35 
5.5 64 147.01 5.40 
2:5  
3 65 191.44 9.22 
5.5 65 149.71 6.81 
  Note: These data refers to a nanoparticles concentration around 3 mg/mL. 
 The parameter used for comparative analysis was the µg 5-Fu per mg of nanoparticles (µg 5-
Fu/mg NPs) because the EE does not consider the nanoparticles concentration used in the loading 
procedure, being inadequate for an equivalent comparison. The values were similar to those previously 
obtained for chitosan and chitosan-collagenase NPs, ranging from 5 to 9 µg 5-Fu per mg of NPs. 
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Figure 4.17 – Graphical representation of 5-Fu loading outcomes for chitosan-collagenase nanoparticles 
synthesized with a genipin:polymer ratio of 1:10, 1:5, 2:5 and 10:1. 
 
 The encapsulation results show higher loads for pH 3 than pH 5.5, suggesting that the network 
swelling is enhanced by acidity increase. 
 Besides, higher encapsulation values were obtained for chitosan-collagenase NPs with higher 
crosslinker content, although there is no linear trend with crosslinker increase. 
The release efficiency (RE) was calculated by the formula: 
 E     =
 5 Fu supernatant
 5 Fu loaded
 100 
The release data collected regarding the tested pH and crosslinking conditions are summarized in 
Table 4.7. 
Table 4.7 - Estimated parameters obtained by 5-fluorouracil release at pH 5.5 and 3, from the previously loaded 
chitosan-collagenase nanoparticles, synthesized using genipin:polymer ratios of 1:10, 1:5 and 2:5. 
Genipin:polymer 
ratio 
Load 
pH 
Release 
pH 
RE (%) 
[5-Fu] 
(µM) 
µg 5-Fu/mg NPs 
1 : 10 
3 
3 10.1 21.76 0.86 
5.5 1.9 4,00 0.16 
5.5 
3 11.6 16,00 0.70 
5.5 5.9 8.07 0.35 
1 : 5 
3 
3 4.4 8,00 0.32 
5.5 6.6 12.07 0.49 
5.5 
3 15.6 22.91 0.84 
5.5 4.5 6.69 0.25 
2 :5 
3 
3 4.8 9.15 0.44 
5.5 2.8 5.38 0.26 
5.5 
3 5.3 8,00 0.37 
5.5 0.9 1.31 0.06 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
 1:10  1:5  2:5  10:1 
µ
g
 5
-F
u
/m
g
 N
P
s 
Genipin:polymer ratio 
pH 3 
pH 5,5 
41 
 
 
 As shown in Table 2.1, the released amounts of 5-fluoroutacil per mg of NPs were low. 
However, those values can be analysed for comparative purposes regarding the study of pH and 
crosslinking influence in nanoparticles swelling. The results are graphically represented in Figure 
4.18. 
 
Figure 4.18 - Graphical representation of 5-Fu release outcomes from previously loaded chitosan-collagenase 
nanoparticles synthesized with a genipin:polymer ratio of 1:10, 1:5, 2:5 and 10:1. 
   
 Concerning the crosslinking influence, the system with high crosslinker content 
(genipin:polymer ratio of 2:5)  presented, in general, the higher loads (Figure 4.17) and the lower 
release values (Figure 4.18). This suggests that the drug entrapment is influenced not only by the 
network swelling, but also by its internal organisation. Nanoparticles with lower crosslinking degrees 
form networks with higher porosity, making drug migration easier. Larger pores confer less 
entrapment capacity to the network but higher release efficiency. Since that behaviour is not uniform 
for linear crosslinker variations, further developments to achieve the most favourable genipin:polymer 
ratio in terms of drug entrapment and release rates should be done. For medical purposes, it is crucial 
to find the best equilibrium between the drug dose and its sustained and controlled release. 
 Regarding pH, it was observed that, in most cases, the load and release at pH 3 promoted 
higher drug liberation and load and release at pH 5.5 presented the lower liberation values. The data in 
Figure 4.18, were rearranged to allow a detailed analysis regarding pH influence - Figure 4.19. 
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Figure 4.19 - Graphical representation of 5-Fu release outcomes from chitosan-collagenase nanoparticles 
submitted to equal load pH (top) and equal release pH (bottom). 
 
 Analysing independently the release outcomes for equal load pH and equal release pH, a 
major release enhancement for nanoparticles in which the load and/or release occurred at pH 3 is 
observed. 
 In summary, according to the observations regarding pH, it is possible to postulate that 
network swelling increases with acidity. The crosslinking degree influences the network swelling, but 
it is not yet possible to define a pattern. 
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5. CONCLUSIONS 
 
The presented work focused on the concurrent development of two polymeric nanoparticulate systems, 
mPEG-co-PCL and chitosan-collagenase nanoparticles, aiming to target metastatic colorectal cancer. 
The encapsulation of PEITC in mPEG-co-PCL NPs was tested for the first time, applying a green 
approach, using empty and C6-loaded mPEG-co-PCL NPs as control. In parallel, a chemical approach 
was applied for the development of chitosan-collagenase nanoparticles, as a novel system, using 
chitosan NPs as control. Encapsulation and release assays were performed for this system, using 5-
fluorouracil.  
 Regarding the mPEG-co-PCL nanoparticles, it was possible to reproduce the empty 
nanoparticles with parameters in agreement with the literature. The C6-loaded nanoparticles presented 
a size range higher than the procedure-based publications and high contents of non-encapsulated 
coumarin-6, suggesting low encapsulation efficiency. In turn, the results obtained for PEITC 
encapsulation in mPEG-co-PCL does not allow to reliably confirm an efficient synthesis of PEITC-
loaded nanoparticles, needing further optimization. Since the development of this system did not 
present reproducibility in the predicted time, and given the promising results obtained in parallel for 
chitosan-collagenase nanoparticles, the remaining tasks focused on this novel system. 
 The chitosan-collagenase nanoparticles were efficiently developed, revealing spherical shape 
and broad sizes, ranging from 100 to 500 nm, in comparison to chitosan-control nanoparticles, 
reproduced in sizes under 50 nm. It was possible to optimize the syntheses yield up to values around 
65%. 
 Concerning the encapsulation and release assays, it was possible to obtain loads ranging from 
5 to 9 µg of 5-Fu per mg of nanoparticles, acceptable to submit to in vitro assays, already initiated. 
However the release was significantly low, in ranges of 0.06 to 0.86 5-Fu µg per NPs mg. The study of 
the influence of pH and crosslinking degree in nanoparticles network swelling suggests swelling 
enhancement in more acidic pH and lower crosslinking percentage. In turn, the results obtained for 
different crosslink contents support the hypothesis of an opposite effect for loading and release, in 
which crosslinking enhancement confers to the network higher entrapment capacity but lower release 
efficiency. 
 
 The development of both PEITC-loaded mPEG-co-PCL and chitosan-collagenase 
nanosystems is expected to continue in future work, as further described in the next section.  
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6. FUTURE WORK 
 
The future tasks include two different work plans, comprising PEITC-loaded mPEG-co-PCL and 
chitosan-collagenase nanoparticles, respectively. 
 The development of PEITC-loaded mPEG-co-PCL nanoparticles is in preliminary stages, 
needing full optimization from the initial synthesis steps to the characterization. 
 Concerning chitosan-collagenase nanoparticles, that has been the main target of the work 
developed during this thesis, it is necessary to further characterize the nanoparticulate system. A 
complete physicochemical characterization will allow to direct its features to the target goals in a more 
profitable perspective. 
 Moreover, the load and release capacity of the nanosystems needs to be further studied in 
several parameters. Additional tests regarding pH and crosslinking influence have to be done to 
validate the postulated hypotheses. Assays for studying this field had already been designed, including 
time variable, to achieve an equilibrium between nanoparticles drug content and its release efficiency, 
with the potential to promote a sustained and controlled release in a pharmacological perspective.  
 Since chitosan-collagenase nanoparticles are already involved in in vitro assays, and 
preliminary results reveal agglomeration as an obstacle, current developments are focused on the study 
of chitosan-collagenase nanoparticles stability in solution. 
 Besides, it is planned for a near future the encapsulation of curcumin, a natural compound 
with antitumor features, proven potential for chemotherapeutic treatment of colorectal cancer 
(Chauhan, 2002) and synergetic effect when combined with 5-fluorouracil (Toden et al., 2014). The 
projected tasks aim to test in vitro the individual effects of 5-fluorouracil and curcumin, their synergy 
and the contribution of their individual and combined encapsulation in chitosan-collagenase 
nanoparticles, in terms of targeting and release efficiency. 
 Furthermore, since both mPEG-co-PCL and chitosan-collagenase nanoparticles were planned 
to be specialized for specific recognition of metastasis from colorectal cancer, functionalization 
pathways are being prepared for surface modification with a peptide to recognize a biomarker 
overexpressed in primary and metastatic colorectal carcinoma cells. 
 A manuscript is being prepared for chitosan-collagenase nanoparticles, expected to be 
submitted early next year. 
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8. APPENDIX 
 
Figure 8.1 - 1H-NMR spectrum obtained for mPEG-co-PCL and its corresponding chemical structure 
(represented by letters) by a) Xiong et al., 2015 and b) Baimark, 2009. 
 
Figure 8.2 – a) Schematic representation of ε-caprolactone ring opening polymerization; b) NMR spectrum of 
poly(ε-caprolactone) and corresponding chemical groups. Adapted from Long et al., 2010. 
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‘Wingardium leviosa’ 
Levita! Mais, sempre mais alto! 
O mais longe que puderes… 
…e mais além! 
